Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report

E-ISSN： 1873-5592|17|15|1755-1760

ISSN： 1389-4501

Source： Current Drug Targets, Vol.17, Iss.15, 2016-12, pp. : 1755-1760

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review

Current Drug Targets, Vol. 18, Iss. 10, 2017-07 ,pp. : 1204-1213

Bentham Science Publishers

Access to resources Recommend Favorite

Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review

Current Drug Metabolism, Vol. 16, Iss. 2, 2015-01 ,pp. : 97-104

Bentham Science Publishers

Access to resources Recommend Favorite

Pazopanib: The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

By Keisner Sidney V. Shah Sachin R.

Drugs, Vol. 71, Iss. 4, 2011-03 ,pp. : 443-454

Adis International

Access to resources Recommend Favorite

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

By Sonpavde Guru Hutson Thomas E Sternberg Cora N

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 2, 2008-02 ,pp. : 253-261

Informa Healthcare

Access to resources Recommend Favorite

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 11, 2015-11 ,pp. : 660-668

John Wiley & Sons Inc

Access to resources Recommend Favorite